Please login to the form below

Not currently logged in
Email:
Password:

Selexys

This page shows the latest Selexys news and features for those working in and with pharma, biotech and healthcare.

Novartis buys blood disease specialist Selexys

Novartis buys blood disease specialist Selexys

Novartis buys blood disease specialist Selexys. $665m deal prompted by positive phase II data for sickle cell disease therapy. ... Novartis has bolstered its portfolio with a deal to buy US company Selexys Pharmaceuticals, which has a drug for sickle

Latest news

  • Novartis signs $665m option deal with Selexys Novartis signs $665m option deal with Selexys

    Novartis signs $665m option deal with Selexys. Would acquire biotech company and its sickle cell disease drug. ... Patients with sickle cell disease endure great suffering and frequent hospitalisation due to painful vaso-occlusive crises," said Selexys'

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    Options exercised. The largest deal in our table this month is the acquisition of Selexys Pharmaceuticals by Novartis for $665m in upfront, acquisition and milestone payments. ... Licensor Acquired/ Licensee Acquirer. Product/ Technology. Deal Type.

  • Pharma deals during September 2012 Pharma deals during September 2012

    Last but not least. The final deal under the spotlight this month is Novartis' option to acquire Selexys Pharmaceuticals upon successful phase II studies in SelG1, a humanised mAb targeting ... Dual-affinity re-targeting (DART) platform technology for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics